Prosecution Insights
Last updated: November 15, 2026
Application No. 18/022,099

ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF

Non-Final OA §112
Filed
Feb 17, 2023
Priority
Aug 20, 2020 — provisional 63/068,342 +2 more
Examiner
BERHANE, SELAM
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ambrx Inc.
OA Round
2 (Non-Final)
59%
Grant Probability
Moderate
2-3
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
57 granted / 96 resolved
-0.6% vs TC avg
Strong +58% interview lift
Without
With
+57.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
41 currently pending
Career history
150
Total Applications
across all art units

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Election/Restrictions Applicant’s election without traverse of Group I, claims 54-68 and species: an anti-CD70 antibody and SEQ ID NO: 27 in the reply filed 12/18/2025 is acknowledged. Claims 56, 58, 60, 62, 69-70 are withdrawn from consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions and species, there being no allowable generic or linking claims. Election was made in the reply filed 12/18/2025. Claims 54, 64, 66, 68, and new claims 72-81 are now under consideration in the instant Office Action. Withdrawn Objections Objections to claims 54-55 and 66 due to minor informalities are hereby withdrawn in view of amendments to the claims to obviate the issue. Withdrawn Rejections Rejections of claims 65 and 67 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter are hereby withdrawn in view of amendments to the claims. Rejections of claims 54-55, 64-66, and 68 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement are hereby withdrawn in view of amendments to the claims. Rejections of claims 54-55, 64-66, and 68 under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for an immunoconjugate with defined sequences SEQ ID NOs: 25-27 for the anti-CD70 antibody and a complete structure for the TLR agonist, does not reasonably provide enablement for any immunoconjugate comprising a TLR agonist conjugated to an antibody without defined sequences are hereby withdrawn in view of amendments to the claims. Rejections of claims 54-55, 64-66, and 68 under 35 U.S.C. 102(a)(2) as being anticipated by Ambrx Inc. (WO 2020/168017 A1, in IDS filed 02/17/2023) are hereby withdrawn in view of amendments to the claims that alter the scope of the claims. New Rejections Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. New claims 75 and 81 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. With regards to new claim 75, the claim currently reads “wherein SEQ ID NO: 27 comprises a para-acetyl phenylalanine at position 114 according to Kabat numbering, wherein the para-acetyl phenylalanine is covalently linked to the TLR agonist via an oxime bond.” As currently recited, it is unclear if the para-acetyl phenylalanine is to be included in the primary structure of the antibody or as a post translation modification to its higher order structures. The sequence listing for SEQ ID NO: 27 lists leucine as the amino acid at position 114. As such, the claim can have multiple interpretations and is considered indefinite as written. Clarifying the wording of the claims such that which amino acid is intended at that position and the additional modifications that can be made at the position recited in the claim would obviate this rejection. With regards to claim 81, the claim recites that the immunoconjugate thereof comprises “(ii) one or more: Fab mutation(s), (Fab')2 mutation(s), Fv mutation(s), or single chain Fv (scFv) mutation(s)”. As currently recited, the mutations that belong to the Fab, (Fab’)2, Fv, and scFv portions of the antibody are unclear because these antibody fragments all contain antigen binding regions, which are highly specific to particular antigens. Mutations in the amino acid sequences of such fragments would alter the identity of the antibodies, and it is unclear what modification or mutations are encompassed within the scope of the claims. Therefore, the mutations recited in the claims render the claim indefinite. Allowable Subject Matter Claims 54, 64, 66, 68, 72-74, and 76-80 are allowable. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SELAM BERHANE whose telephone number is (571)272-6138. The examiner can normally be reached Monday - Friday, 9-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at 571-272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SELAM BERHANE/Examiner, Art Unit 1675 /JEFFREY STUCKER/Supervisory Patent Examiner, Art Unit 1675
Read full office action

Prosecution Timeline

Feb 17, 2023
Application Filed
Jun 13, 2024
Response after Non-Final Action
Mar 13, 2026
Non-Final Rejection (signed) — §112
Apr 21, 2026
Non-Final Rejection mailed — §112
Jul 20, 2026
Response Filed
Sep 23, 2026
Final Rejection mailed — §112
Nov 03, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774346
Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof
4y 10m to grant Granted Oct 27, 2026
Patent 12692311
ANTI-MDR1 ANTIBODIES AND USES THEREOF
4y 0m to grant Granted Jul 28, 2026
Patent 12673090
TREATMENT OF CANCERS USING sEphB4-HSA FUSION PROTEINS
4y 9m to grant Granted Jul 07, 2026
Patent 12662541
ANTIBODY-DRUG CONJUGATES AGAINST THE RECEPTOR TYROSINE KINASE EPHA5
3y 7m to grant Granted Jun 23, 2026
Patent 12637509
TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D, AND CD3
4y 3m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

2-3
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+57.6%)
Moderate
PTA Risk
Based on 96 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month